All In Biotech

Drug Trial Radar · NCT02101853

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 669 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

669

Actual

Start

Dec 17, 2014

Primary completion

Jun 30, 2021

Study completion Sep 16, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 31 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab may allow the body's immune system to attack and destroy some types of leukemia cells. It is not yet known whether blinatumomab is more effective than standard combination chemotherapy in treating relapsed B-cell acute lymphoblastic leukemia.

Conditions

  • Recurrent B Acute Lymphoblastic Leukemia

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Undergo allogeneic HSCT

  • AsparaginaseDrug

    Given IM or IV

  • BlinatumomabBiological

    Given IV

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IT and IV or SC

  • DexamethasoneDrug

    Given PO or IV

  • EtoposideDrug

    Given IV

  • Leucovorin CalciumDrug

    Given IV or PO

  • MercaptopurineDrug

    Given PO

  • MethotrexateDrug

    Given IT, IV, and PO

  • MitoxantroneDrug

    Given IV

  • Mitoxantrone HydrochlorideDrug

    Given IV

  • PegaspargaseDrug

    Given IV

  • Pharmacological StudyOther

    Correlative studies

  • Radiation TherapyRadiation

    Undergo cranial radiation therapy

  • Therapeutic HydrocortisoneDrug

    Given IT

  • ThioguanineDrug

    Given PO

  • VincristineDrug

    Given IV

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse PatientsTime frame: Up to 2 years from date of randomization
  2. Disease Free Survival (DFS) of Low Risk (LR) Relapse PatientsTime frame: Up to 3 years from date of randomization

Locations

186 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • USA Health Strada Patient Care Center

    Mobile, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Banner Children's at Desert

    Mesa, Arizona

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Mattel Children's Hospital UCLA

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • Palms West Radiation Therapy

    Loxahatchee Groves, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Arnold Palmer Hospital for Children

    Orlando, Florida

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.